-$0.17 EPS Expected for Cardlytics Inc (CDLX) This Quarter

Equities research analysts expect Cardlytics Inc (NASDAQ:CDLX) to post ($0.17) earnings per share for the current quarter, Zacks reports. Five analysts have made estimates for Cardlytics’ earnings, with estimates ranging from ($0.26) to ($0.05). Cardlytics posted earnings per share of ($0.18) in the same quarter last year, which would indicate a positive year over year growth rate of 5.6%. The business is scheduled to issue its next quarterly earnings report on Monday, March 18th.

On average, analysts expect that Cardlytics will report full year earnings of ($0.86) per share for the current year, with EPS estimates ranging from ($0.95) to ($0.73). For the next financial year, analysts forecast that the company will post earnings of ($0.78) per share, with EPS estimates ranging from ($1.03) to ($0.31). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Cardlytics.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Tuesday, November 13th. The company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.48. The business had revenue of $34.58 million for the quarter, compared to analysts’ expectations of $37.62 million. The firm’s revenue was up 10.1% compared to the same quarter last year.

Several research firms have commented on CDLX. Zacks Investment Research upgraded Cardlytics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 16th. Morgan Stanley decreased their price target on Cardlytics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 14th. JPMorgan Chase & Co. decreased their price target on Cardlytics from $31.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 14th. Raymond James decreased their price target on Cardlytics from $23.00 to $20.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 14th. Finally, Bank of America upgraded Cardlytics from a “neutral” rating to a “buy” rating and set a $15.00 price target on the stock in a research report on Tuesday, January 15th. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $22.38.

NASDAQ CDLX opened at $17.15 on Friday. The stock has a market cap of $332.94 million and a price-to-earnings ratio of -2.14. Cardlytics has a 52 week low of $9.80 and a 52 week high of $28.29. The company has a current ratio of 3.04, a quick ratio of 3.04 and a debt-to-equity ratio of 0.91.

In related news, insider Kirk Somers sold 26,870 shares of the company’s stock in a transaction that occurred on Wednesday, December 12th. The shares were sold at an average price of $13.50, for a total value of $362,745.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO David Thomas Evans sold 27,147 shares of the company’s stock in a transaction that occurred on Tuesday, December 11th. The stock was sold at an average price of $13.50, for a total transaction of $366,484.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 108,503 shares of company stock worth $1,464,517.

Several hedge funds have recently bought and sold shares of CDLX. New York State Common Retirement Fund increased its position in shares of Cardlytics by 80.0% in the fourth quarter. New York State Common Retirement Fund now owns 9,000 shares of the company’s stock worth $97,000 after purchasing an additional 4,000 shares during the last quarter. First Mercantile Trust Co. increased its position in shares of Cardlytics by 115.0% in the fourth quarter. First Mercantile Trust Co. now owns 12,893 shares of the company’s stock worth $140,000 after purchasing an additional 6,897 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Cardlytics by 72.4% in the third quarter. Wells Fargo & Company MN now owns 8,004 shares of the company’s stock worth $201,000 after purchasing an additional 3,361 shares during the last quarter. TIAA CREF Investment Management LLC bought a new position in shares of Cardlytics in the third quarter worth approximately $202,000. Finally, Schwab Charles Investment Management Inc. bought a new position in shares of Cardlytics in the second quarter worth approximately $214,000. Institutional investors own 74.23% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Featured Story: Treasury Bonds

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit